Acathia Capital Increases Stake in Swedish Savings Platform Futur
3.12.2024 17:46:00 CET | Business Wire | Press release
Acathia Capital has signed its second GP-led secondary transaction thereby increasing its stake in Futur, Sweden's leading pension and savings platform. For this investment Acathia Capital is backed by Montana Capital Partners, a global private equity secondaries investment manager and part of PGIM, the global investment management business of Prudential Financial, Inc. (NYSE: PRU). MCP serves as the main investor in this transaction, alongside a German insurance company.
Since 2019, Acathia Capital and Nordic private equity manager Polaris Private Equity have jointly lead-managed the investment in Futur alongside 3 passive co-investors. In this transaction, Acathia Capital acquired shares from one co-investor through its new vehicle Fjord Pension SCS.
The transaction is another milestone in the journey of Acathia Capital’s successful investment strategy of full conviction investments on a deal-by-deal basis in the financial services sector. Acathia now manages over EUR 300 million AuM.
Futur exemplifies the power of digitalization in the savings market. The company has redefined Sweden’s life insurance market through cost and service leadership, gaining significant market share through end-to-end digitalization and full scalability.
Thanks to its fully digitalized operations, Futur benefits from unique competitive advantages, including:
- Best-in-class partner satisfaction
- Unrivalled cost efficiency
- Leading product innovation capability
Dr. Thomas Schmitt, Managing Partner at Acathia Capital, remarked: “Since our investment in Futur began in 2019, Futur has tripled its assets under management to SEK 240bn. and more than quadrupled its profits, establishing itself as a market leader in Sweden.”
Torgny Johansson, CEO of Futur, says: “We stick to our strategy, to be independent and focus on simplicity for our partners as well as our joint customers.”
About Futur
Futur is a technology-powered pension and savings platform with a life insurance license. It offers long-term savings and insurance cover, with a particular focus on occupational pension and capital insurance. The platform offers leading efficiency, simplicity and access to an independent, quality proofed fund offering. Futur administers over SEK 240bn AuM in 2024 in the form of unit-linked insurance policies.
About Acathia Capital
Acathia Capital specializes in investments in fully regulated insurers and banks across Europe and manages over EUR 300 million in investments for German and Swiss institutional investors. With a track record of creating top-quartile returns for investors, Acathia Capital drives transformative growth in its portfolio companies.
The closing of the transaction is subject to approval of the Swedish Financial Supervisory Authority.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203919861/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom